---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-076674"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:29:54.445630+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Inhibikase Therapeutics holds R&D Day; presentation content not fully available in filing

## Summary
- Company presented to investors at R&D Day on March 22, 2023.
- The 8-K includes presentation as Exhibit 99.1 but only title slide and disclaimer are visible in the filing excerpt.
- No specific pipeline data, financial figures, or clinical milestones are extractable from the provided text.
- Investors should consult the full presentation on the company's website or other SEC filings for details.

## SEC filing metadata
- accession: 0001193125-23-076674
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312523076674/0001193125-23-076674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312523076674/d485707d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-076674
- JSON: https://secwatch.observer/filing/0001193125-23-076674.json
- Plain text: https://secwatch.observer/filing/0001193125-23-076674.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.